Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06578195
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-20
Brief Title:
ASSESS ALL ALS Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
ASSESS ALL ALS - Longitudinal Biomarker Study for Symptomatic ALS and Control Participants
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples clinical information and measurements from Amyotrophic Lateral Sclerosis ALS symptomatic ALS gene carriers and control cohorts This consortium is begin funded by the National Institutes of HealthNational Institute of Neurological Disorders and Stroke NIHNINDS and managed by two clinical coordinating centers CCC at Barrow Neurological Institute and Massachusetts General Hospital The clinical sites are distributed across the country and led by a group of collaborative principal investigators Once data and samples are collected and harmonized it will be made available to research community for future research into ALS and related neurological diseases
ASSESS protocol is specific for symptomatic ALS and control participants This protocol includes both on-site and off-siteremote participants The participants will be followed for 24 months 2 years and will include collection of medical history clinical outcomes and blood samples once in 4 months Additionally the participants will complete patient reported outcomes and speech recordings once a month Participants who are coming into clinic may also provide optional Cerebrospinal Fluid CSF samples
ASSESS protocol is specific for symptomatic ALS and control participants This protocol includes both on-site and off-siteremote participants The participants will be followed for 24 months 2 years and will include collection of medical history clinical outcomes and blood samples once in 4 months Additionally the participants will complete patient reported outcomes and speech recordings once a month Participants who are coming into clinic may also provide optional Cerebrospinal Fluid CSF samples
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None